{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T08:53:55Z","timestamp":1788512035690,"version":"build-2803163510"},"reference-count":109,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004612","name":"Funda\u00e7\u00e3o Arauc\u00e1ria de Apoio ao Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico do Paran\u00e1","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004612","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordination for the improvement of Higher Education Personnel","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"National Council for Scientific and Technological Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chemico-Biological Interactions"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.cbi.2026.111951","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T15:39:13Z","timestamp":1769701153000},"page":"111951","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Molecular actions of sepantronium bromide (YM155) on survivin-dependent cell death in cancer and beyond"],"prefix":"10.1016","volume":"427","author":[{"given":"Steffanni S.A.","family":"Marques","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mateus E.T.","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9dipo G.","family":"Fran\u00e7a-Lara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline K.","family":"Menuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrielle S.","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa A.","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciana F.C.M.","family":"Zischler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea N.","family":"Moreno-Amaral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8676-134X","authenticated-orcid":false,"given":"Selene","family":"Elifio-Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cbi.2026.111951_bib1","doi-asserted-by":"crossref","first-page":"8014","DOI":"10.1158\/0008-5472.CAN-07-1343","article-title":"YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts","volume":"67","author":"Nakahara","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.cbi.2026.111951_bib2","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/j.1349-7006.2010.01834.x","article-title":"Broad spectrum and potent antitumor activities of YM155, a novel small-molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models","volume":"102","author":"Nakahara","year":"2011","journal-title":"Cancer Sci."},{"key":"10.1016\/j.cbi.2026.111951_bib3","doi-asserted-by":"crossref","DOI":"10.1242\/jcs.223826","article-title":"Survivin at a glance","volume":"132","author":"Wheatley","year":"2019","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.cbi.2026.111951_bib4","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nm0897-917","article-title":"A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma","volume":"3","author":"Ambrosini","year":"1997","journal-title":"Nat. Med."},{"key":"10.1016\/j.cbi.2026.111951_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2024.122788","article-title":"Survivin (BIRC5): implications in cancer therapy","volume":"350","author":"Siragusa","year":"2024","journal-title":"Life Sci."},{"key":"10.1016\/j.cbi.2026.111951_bib6","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.bbrc.2012.07.103","article-title":"Sepantronium bromide (YM155) induces disruption of the ILF3\/p54(nrb) complex, which is required for survivin expression","volume":"425","author":"Yamauchi","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.cbi.2026.111951_bib7","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan-a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst. Rev."},{"issue":"M111","key":"10.1016\/j.cbi.2026.111951_bib8","article-title":"Interleukin enhancer-binding factor 3\/NF110 is a target of YM155, a suppressant of survivin","volume":"11","author":"Nakamura","year":"2012","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.cbi.2026.111951_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8030408","article-title":"Epigenetic changes at the Birc5 promoter induced by YM155 in Synovial Sarcoma","volume":"8","author":"Mika","year":"2019","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.cbi.2026.111951_bib10","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25010216","article-title":"Therapeutic efficacy of YM155 to regulate an epigenetic enzyme in major subtypes of RCC","volume":"25","author":"Hong","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cbi.2026.111951_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2022.106343","article-title":"YM155 inhibits neuroblastoma growth through degradation of MYCN: a new role as a USP7 inhibitor","volume":"181","author":"Li","year":"2023","journal-title":"Eur. J. Pharmaceut. Sci."},{"key":"10.1016\/j.cbi.2026.111951_bib12","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12051080","article-title":"YM155-Adapted cancer cell lines reveal drug-induced heterogeneity and enable the identification of biomarker candidates for the acquired resistance setting","volume":"12","author":"Michaelis","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.cbi.2026.111951_bib13","first-page":"179","article-title":"Suppression of survivin promoter activity by YM155 involves disruption of Sp1-DNA interaction in the survivin core promoter","volume":"3","author":"Cheng","year":"2012","journal-title":"Int J Biochem Mol Biol"},{"key":"10.1016\/j.cbi.2026.111951_bib14","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/jop.12299","article-title":"YM155 induces apoptosis through downregulation of specificity protein 1 and myeloid cell leukemia-1 in human oral cancer cell lines","volume":"44","author":"Sachita","year":"2015","journal-title":"J. Oral Pathol. Med."},{"key":"10.1016\/j.cbi.2026.111951_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2019.114857","article-title":"Autophagic HuR mRNA degradation induces survivin and MCL1 downregulation in YM155-treated human leukemia cells","volume":"387","author":"Chiou","year":"2020","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.cbi.2026.111951_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114544","article-title":"Inhibition of Sp1-mediated survivin and MCL1 expression cooperates with SLC35F2 and myeloperoxidase to modulate YM155 cytotoxicity to human leukemia cells","volume":"188","author":"Chiou","year":"2021","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.cbi.2026.111951_bib17","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1039\/D0MD00383B","article-title":"Generation of reactive oxygen species is the primary mode of action and cause of survivin suppression by sepantronium bromide (YM155)","volume":"12","author":"Wani","year":"2021","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.cbi.2026.111951_bib18","doi-asserted-by":"crossref","first-page":"33589","DOI":"10.18632\/oncotarget.26096","article-title":"Adaptation to chronic exposure to sepantronium bromide (YM155), a prototypical survivin suppressant is due to persistent DNA damage-response in breast cancer cells","volume":"9","author":"Wani","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.cbi.2026.111951_bib19","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1128\/MCB.00671-14","article-title":"Adhesion molecule-mediated hippo pathway modulates hemangioendothelioma cell behavior","volume":"34","author":"Tsuneki","year":"2014","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.cbi.2026.111951_bib20","first-page":"3779","article-title":"Clinicopathological and functional implications of the inhibitor of apoptosis proteins survivin and XIAP in esophageal cancer","volume":"15","author":"Dizdar","year":"2018","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.cbi.2026.111951_bib21","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.ejca.2011.10.012","article-title":"Targeted BIRC5 silencing using YM155 causes cell death in neuroblastoma cells with low ABCB1 expression","volume":"48","author":"Lamers","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.cbi.2026.111951_bib22","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1159\/000430245","article-title":"The mechanism of radiosensitization by YM155, a novel small molecule inhibitor of survivin expression, is associated with DNA damage repair","volume":"37","author":"Hu","year":"2015","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.cbi.2026.111951_bib23","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.bbrc.2013.04.036","article-title":"YM155 induces caspase-8 dependent apoptosis through downregulation of survivin and Mcl-1 in human leukemia cells","volume":"435","author":"Feng","year":"2013","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.cbi.2026.111951_bib24","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1124\/jpet.113.204743","article-title":"Survivin inhibitor YM-155 sensitizes tumor necrosis factor- related apoptosis-inducing ligand-resistant glioma cells to apoptosis through Mcl-1 downregulation and by engaging the mitochondrial death pathway","volume":"346","author":"Premkumar","year":"2013","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.cbi.2026.111951_bib25","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.bcp.2011.07.064","article-title":"Mcl-1 downregulation by YM155 contributes to its synergistic anti-tumor activities with ABT-263","volume":"82","author":"Tang","year":"2011","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.cbi.2026.111951_bib26","doi-asserted-by":"crossref","first-page":"18445","DOI":"10.18632\/oncotarget.4315","article-title":"YM155, a survivin suppressant, triggers PARP-dependent cell death (parthanatos) and inhibits esophageal squamous-cell carcinoma xenografts in mice","volume":"6","author":"Zhao","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.cbi.2026.111951_bib27","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1111\/bph.12416","article-title":"Parthanatos: mitochondrial-linked mechanisms and therapeutic opportunities","volume":"171","author":"Fatokun","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.cbi.2026.111951_bib28","article-title":"Molecular mechanisms of parthanatos and its role in diverse diseases","volume":"23","author":"Huang","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cbi.2026.111951_bib29","doi-asserted-by":"crossref","first-page":"11625","DOI":"10.18632\/oncotarget.7299","article-title":"Dioxonaphthoimidazoliums AB1 and YM155 disrupt phosphorylation of p50 in the NF-\u03baB pathway","volume":"7","author":"Ho","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.cbi.2026.111951_bib30","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-28213-3","article-title":"Anti-survivin effect of the small molecule inhibitor YM155 in RCC cells is mediated by time-dependent inhibition of the NF-\u03baB pathway","volume":"8","author":"Sim","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cbi.2026.111951_bib31","doi-asserted-by":"crossref","first-page":"249","DOI":"10.21873\/cgp.20083","article-title":"Effects of sepantronium bromide (YM-155) on the whole transcriptome of MDA-MB-231 cells: highlight on impaired ATR\/ATM Fanconi Anemia DNA damage response","volume":"15","author":"Mazzio","year":"2018","journal-title":"Cancer Genomics Proteomics"},{"key":"10.1016\/j.cbi.2026.111951_bib32","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13045-015-0132-6","article-title":"YM155 potently kills acute lymphoblastic leukemia cells through activation of the DNA damage pathway","volume":"8","author":"Chang","year":"2015","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.cbi.2026.111951_bib33","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1158\/1535-7163.MCT-21-0619","article-title":"YM155 induces DNA damage and cell death in anaplastic thyroid cancer cells by inhibiting DNA topoisomerase II\u03b1 at the ATP-Binding site","volume":"21","author":"Mackay","year":"2022","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.cbi.2026.111951_bib34","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-17446-y","article-title":"Ym155 localizes to the mitochondria leading to mitochondria dysfunction and activation of AMPK that inhibits BMP signaling in lung cancer cells","volume":"12","author":"Mondal","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cbi.2026.111951_bib35","doi-asserted-by":"crossref","DOI":"10.1242\/jcs.247379","article-title":"Mitochondrial survivin reduces oxidative phosphorylation in cancer cells by inhibiting mitophagy","volume":"133","author":"Townley","year":"2020","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.cbi.2026.111951_bib36","doi-asserted-by":"crossref","DOI":"10.1242\/jcs.263689","article-title":"Survivin can alter mitochondrial architecture by regulating phosphatidylethanolamine synthesis","volume":"138","author":"Dunajova","year":"2025","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.cbi.2026.111951_bib37","doi-asserted-by":"crossref","first-page":"13476","DOI":"10.18632\/oncotarget.3638","article-title":"YM155 potently triggers cell death in breast cancer cells through an autophagy-NF-kB network","volume":"6","author":"V\u00e9quaud","year":"2015","journal-title":"Oncotarget"},{"issue":"Suppl 6","key":"10.1016\/j.cbi.2026.111951_bib38","doi-asserted-by":"crossref","first-page":"S217","DOI":"10.1016\/j.htct.2024.05.012","article-title":"The survivin\/XIAP suppressant YM155 impairs clonal growth and induces apoptosis in JAK2(V617F) cells","volume":"46","author":"Carlos","year":"2024","journal-title":"Hematol Transfus Cell Ther"},{"key":"10.1016\/j.cbi.2026.111951_bib39","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/bph.12935","article-title":"YM155 down-regulates survivin and XIAP, modulates autophagy and induces autophagy-dependent DNA damage in breast cancer cells","volume":"172","author":"Cheng","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.cbi.2026.111951_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105474","article-title":"YM155 and BIRC5 downregulation induce genomic instability via autophagy-mediated ROS production and inhibition in DNA repair","volume":"166","author":"Cheng","year":"2021","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.cbi.2026.111951_bib41","doi-asserted-by":"crossref","first-page":"3786","DOI":"10.1016\/j.bbadis.2018.10.015","article-title":"YM155 sensitizes non-small cell lung cancer cells to EGFR-tyrosine kinase inhibitors through the mechanism of autophagy induction","volume":"1864","author":"Dai","year":"2018","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"10.1016\/j.cbi.2026.111951_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.mito.2024.101932","article-title":"SIRT6 suppresses colon cancer growth by inducing apoptosis and autophagy through transcriptionally down-regulating Survivin","volume":"78","author":"Liu","year":"2024","journal-title":"Mitochondrion"},{"key":"10.1016\/j.cbi.2026.111951_bib43","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2015.139","article-title":"Dual induction of apoptotic and autophagic cell death by targeting survivin in head neck squamous cell carcinoma","volume":"6","author":"Zhang","year":"2015","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.cbi.2026.111951_bib44","doi-asserted-by":"crossref","first-page":"113687","DOI":"10.18632\/oncotarget.22823","article-title":"Elucidating respective functions of two domains BIR and C-helix of human IAP survivin for precise targeted regulating mitotic cycle, apoptosis and autophagy of cancer cells","volume":"8","author":"Hu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.cbi.2026.111951_bib45","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.canlet.2010.12.007","article-title":"Induction of autophagy-dependent apoptosis by the survivin suppressant YM155 in prostate cancer cells","volume":"302","author":"Wang","year":"2011","journal-title":"Cancer Lett."},{"key":"10.1016\/j.cbi.2026.111951_bib46","doi-asserted-by":"crossref","first-page":"9974","DOI":"10.1074\/jbc.M114.600874","article-title":"Cellular inhibitor of apoptosis protein 1 (cIAP1) stability contributes to YM155 resistance in human gastric cancer cells","volume":"290","author":"Jung","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cbi.2026.111951_bib47","doi-asserted-by":"crossref","first-page":"9752","DOI":"10.7150\/thno.63806","article-title":"USP32 confers cancer cell resistance to YM155 via promoting ER-associated degradation of solute carrier protein SLC35F2","volume":"11","author":"Chandrasekaran","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.cbi.2026.111951_bib48","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1158\/1541-7786.MCR-16-0315-T","article-title":"Exploiting AR-Regulated drug transport to induce sensitivity to the Survivin Inhibitor YM155","volume":"15","author":"Nyquist","year":"2017","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.cbi.2026.111951_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2024.116888","article-title":"The SMAC mimetic GDC-0152 is a direct ABCB1-ATPase activity modulator and BIRC5 expression suppressor in cancer cells","volume":"485","author":"Lin","year":"2024","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.cbi.2026.111951_bib50","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/sj.bjc.6605713","article-title":"Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs","volume":"103","author":"Iwasa","year":"2010","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.cbi.2026.111951_bib51","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ygyno.2013.11.013","article-title":"YM155 sensitizes ovarian cancer cells to cisplatin inducing apoptosis and tumor regression","volume":"132","author":"Mir","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.cbi.2026.111951_bib52","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1158\/1535-7163.MCT-12-0167","article-title":"YM155 reverses cisplatin resistance in head and neck cancer by decreasing cytoplasmic survivin levels","volume":"11","author":"Kumar","year":"2012","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.cbi.2026.111951_bib53","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3892\/or.2015.3947","article-title":"Antitumor activity of YM155, a selective survivin suppressant, in combination with cisplatin in hepatoblastoma","volume":"34","author":"Yu","year":"2015","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.cbi.2026.111951_bib54","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.3892\/ijo.2016.3438","article-title":"Survivin selective inhibitor YM155 promotes cisplatin-induced apoptosis in embryonal rhabdomyosarcoma","volume":"48","author":"Ueno","year":"2016","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.cbi.2026.111951_bib55","doi-asserted-by":"crossref","first-page":"5423","DOI":"10.1158\/1078-0432.CCR-10-3410","article-title":"Antitumor activity of YM155, a selective small-molecule survivin suppressant, alone and in combination with docetaxel in human malignant melanoma models","volume":"17","author":"Yamanaka","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cbi.2026.111951_bib56","doi-asserted-by":"crossref","first-page":"R55","DOI":"10.1186\/bcr3666","article-title":"Survivin family proteins as novel molecular determinants of doxorubicin resistance in organotypic human breast tumors","volume":"16","author":"Faversani","year":"2014","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.cbi.2026.111951_bib57","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1292\/jvms.19-0029","article-title":"YM155 enhances the cytotoxic activity of etoposide against canine osteosarcoma cells","volume":"81","author":"Ong","year":"2019","journal-title":"J. Vet. Med. Sci."},{"key":"10.1016\/j.cbi.2026.111951_bib58","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1007\/s00432-014-1734-z","article-title":"YM155 reverses rapamycin resistance in renal cancer by decreasing survivin","volume":"140","author":"Koike","year":"2014","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.cbi.2026.111951_bib59","article-title":"Rapamycin enhances the anti-angiogenesis and anti-proliferation ability of YM155 in oral squamous cell carcinoma","volume":"39","author":"Li","year":"2017","journal-title":"Tumour Biol"},{"key":"10.1016\/j.cbi.2026.111951_bib60","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/1535-7163.MCT-14-1036","article-title":"Targeting survivin inhibits renal cell carcinoma progression and enhances the activity of temsirolimus","volume":"14","author":"Carew","year":"2015","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.cbi.2026.111951_bib61","doi-asserted-by":"crossref","first-page":"75","DOI":"10.21873\/anticanres.11291","article-title":"YM155 reverses Statin resistance in renal cancer by reducing expression of survivin","volume":"37","author":"Nitta","year":"2017","journal-title":"Anticancer Res."},{"key":"10.1016\/j.cbi.2026.111951_bib62","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1002\/cbin.11494","article-title":"Codelivery of survivin inhibitor and chemotherapeutics by tumor-derived microparticles to reverse multidrug resistance in osteosarcoma","volume":"45","author":"Wei","year":"2021","journal-title":"Cell Biol. Int."},{"key":"10.1016\/j.cbi.2026.111951_bib63","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s12032-022-01843-4","article-title":"YM155 and chrysin cooperatively suppress survivin expression in SMARCB1\/INI1-deficient tumor cells","volume":"39","author":"Yoshino","year":"2022","journal-title":"Med. Oncol."},{"key":"10.1016\/j.cbi.2026.111951_bib64","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1158\/1535-7163.MCT-11-0638","article-title":"Overcoming erlotinib resistance in EGFR mutation-positive non-small cell lung cancer cells by targeting survivin","volume":"11","author":"Okamoto","year":"2012","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.cbi.2026.111951_bib65","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1038\/s41598-017-03129-6","article-title":"Lapatinib potentiates cytotoxicity of YM155 in neuroblastoma via inhibition of the ABCB1 efflux transporter","volume":"7","author":"Radic-Sarikas","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cbi.2026.111951_bib66","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1007\/s11538-016-0177-x","article-title":"Mathematical modeling of the role of survivin on dedifferentiation and radioresistance in cancer","volume":"78","author":"Rhodes","year":"2016","journal-title":"Bull. Math. Biol."},{"key":"10.1016\/j.cbi.2026.111951_bib67","doi-asserted-by":"crossref","first-page":"6496","DOI":"10.1158\/1078-0432.CCR-08-0468","article-title":"Radiosensitizing effect of YM155, a novel small-molecule survivin suppressant, in non-small cell lung cancer cell lines","volume":"14","author":"Iwasa","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cbi.2026.111951_bib68","doi-asserted-by":"crossref","first-page":"3770","DOI":"10.1038\/onc.2014.304","article-title":"Survivin as a therapeutic target in Sonic hedgehog-driven medulloblastoma","volume":"34","author":"Brun","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.cbi.2026.111951_bib69","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/hed.26068","article-title":"Restoring apoptosis dysregulation using survivin inhibitor in nasopharyngeal cancer","volume":"42","author":"Shi","year":"2020","journal-title":"Head Neck"},{"key":"10.1016\/j.cbi.2026.111951_bib70","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0153011","article-title":"Targeting survivin enhances chemosensitivity in retinoblastoma cells and orthotopic tumors","volume":"11","author":"Ferrario","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.cbi.2026.111951_bib71","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.2147\/OTT.S166798","article-title":"Inhibition of survivin enhances radiosensitivity of esophageal cancer cells by switching radiation-induced senescence to apoptosis","volume":"11","author":"Liu","year":"2018","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.cbi.2026.111951_bib72","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s13045-014-0062-8","article-title":"Small-molecule survivin inhibitor YM155 enhances radiosensitization in esophageal squamous cell carcinoma by the abrogation of G2 checkpoint and suppression of homologous recombination repair","volume":"7","author":"Qin","year":"2014","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.cbi.2026.111951_bib73","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12967-018-1451-5","article-title":"YM155 decreases radiation-induced invasion and reverses epithelial-mesenchymal transition by targeting STAT3 in glioblastoma","volume":"16","author":"Zhang","year":"2018","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.cbi.2026.111951_bib74","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s13046-024-03079-8","article-title":"Targeting mTOR and survivin concurrently potentiates radiation therapy in renal cell carcinoma by suppressing DNA damage repair and amplifying mitotic catastrophe","volume":"43","author":"Rachamala","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.cbi.2026.111951_bib75","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s11010-011-1166-x","article-title":"An essential role for the Id1\/PI3K\/Akt\/NFkB\/survivin signalling pathway in promoting the proliferation of endothelial progenitor cells in vitro","volume":"363","author":"Li","year":"2012","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.cbi.2026.111951_bib76","doi-asserted-by":"crossref","first-page":"300","DOI":"10.5582\/ddt.2017.01058","article-title":"Both triazolyl ester of ketorolac (15K) and YM155 inhibit the embryonic angiogenesis in ovo (fertilized eggs) via their common PAK1-survivin\/VEGF signaling pathway","volume":"11","author":"Ahn","year":"2017","journal-title":"Drug Discov. Ther."},{"key":"10.1016\/j.cbi.2026.111951_bib77","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1145994","article-title":"Survivin inhibition with YM155 ameliorates experimental pulmonary arterial hypertension","volume":"14","author":"Blanco","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.cbi.2026.111951_bib78","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.3892\/mmr.2016.4977","article-title":"Targeted inhibition of survivin with YM155 promotes apoptosis of hypoxic human pulmonary arterial smooth muscle cells via the upregulation of voltage-dependent K+ channels","volume":"13","author":"Zhang","year":"2016","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.cbi.2026.111951_bib79","doi-asserted-by":"crossref","first-page":"489","DOI":"10.18240\/ijo.2021.04.02","article-title":"YM155 inhibits retinal pigment epithelium cell survival through EGFR\/MAPK signaling pathway","volume":"14","author":"Li","year":"2021","journal-title":"Int. J. Ophthalmol."},{"key":"10.1016\/j.cbi.2026.111951_bib80","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1167\/tvst.11.2.19","article-title":"The role of survivin and transcription factor FOXP1 in scarring after glaucoma surgery","volume":"11","author":"Wang","year":"2022","journal-title":"Transl. Vis. Sci. Technol."},{"key":"10.1016\/j.cbi.2026.111951_bib81","article-title":"Survivin inhibition attenuates EGF-induced epithelial mesenchymal transformation of human RPE cells via the EGFR\/MAPK pathway","volume":"19","author":"Zhu","year":"2024","journal-title":"PLoS One"},{"key":"10.1016\/j.cbi.2026.111951_bib82","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.yexcr.2018.01.037","article-title":"Survivin regulated by autophagy mediates hyperglycemia-induced vascular endothelial cell dysfunction","volume":"364","author":"Xu","year":"2018","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.cbi.2026.111951_bib83","article-title":"TP53RK drives the progression of chronic kidney disease by phosphorylating Birc5","volume":"10","author":"Wu","year":"2023","journal-title":"Adv. Sci. (Weinh.)"},{"key":"10.1016\/j.cbi.2026.111951_bib84","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s10020-025-01162-0","article-title":"Integrated bioinformatics and validation reveal TMEM45A in systemic lupus erythematosus regulating atrial fibrosis in atrial fibrillation","volume":"31","author":"Xu","year":"2025","journal-title":"Mol. Med."},{"key":"10.1016\/j.cbi.2026.111951_bib85","article-title":"STAT3 suppresses cardiomyocytes apoptosis in CVB3-Induced Myocarditis via survivin","volume":"11","author":"Wang","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.cbi.2026.111951_bib86","doi-asserted-by":"crossref","first-page":"3799","DOI":"10.2147\/DDDT.S208707","article-title":"Id-1 promotes reendothelialization in the early phase after vascular injury through activation of NFkB\/survivin signaling pathway","volume":"13","author":"Li","year":"2019","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.cbi.2026.111951_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.vph.2025.107475","article-title":"Survivin in cardiovascular diseases and its therapeutic potential","volume":"159","author":"Mousso","year":"2025","journal-title":"Vasc. Pharmacol."},{"key":"10.1016\/j.cbi.2026.111951_bib88","article-title":"Ablation of survivin in T cells attenuates acute allograft rejection after murine heterotopic heart transplantation by inducing apoptosis","volume":"12","author":"Xu","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cbi.2026.111951_bib89","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1111\/bph.17375","article-title":"Disruption of survivin protein expression by treatment with YM155 accelerates the resolution of neutrophilic inflammation","volume":"182","author":"Fernandes","year":"2025","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.cbi.2026.111951_bib90","doi-asserted-by":"crossref","first-page":"350","DOI":"10.3389\/fmicb.2019.00350","article-title":"Redirecting an anticancer to an antibacterial hit against methicillin-resistant Staphylococcus aureus","volume":"10","author":"Jang","year":"2019","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.cbi.2026.111951_bib91","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens10020253","article-title":"YM155 inhibits NleB and SseK arginine glycosyltransferase activity","volume":"10","author":"Zhu","year":"2021","journal-title":"Pathogens"},{"key":"10.1016\/j.cbi.2026.111951_bib92","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s13238-021-00836-9","article-title":"High-throughput screening identifies established drugs as SARS-CoV-2 PLpro inhibitors","volume":"12","author":"Zhao","year":"2021","journal-title":"Protein Cell"},{"key":"10.1016\/j.cbi.2026.111951_bib93","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1021\/acsptsci.1c00240","article-title":"Validation and invalidation of SARS-CoV-2 papain-like protease inhibitors","volume":"5","author":"Ma","year":"2022","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.cbi.2026.111951_bib94","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1002\/ijc.28239","article-title":"Early gene expression changes by Epstein-Barr virus infection of B-cells indicate CDKs and survivin as therapeutic targets for post-transplant lymphoproliferative diseases","volume":"133","author":"Bernasconi","year":"2013","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.cbi.2026.111951_bib95","doi-asserted-by":"crossref","first-page":"5198","DOI":"10.1200\/JCO.2008.17.2064","article-title":"Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin","volume":"26","author":"Tolcher","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cbi.2026.111951_bib96","doi-asserted-by":"crossref","first-page":"3872","DOI":"10.1158\/1078-0432.CCR-08-1946","article-title":"Phase I study of YM155, a novel survivin suppressant, in patients with advanced solid tumors","volume":"15","author":"Satoh","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cbi.2026.111951_bib99","doi-asserted-by":"crossref","first-page":"4481","DOI":"10.1200\/JCO.2008.21.1862","article-title":"Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer","volume":"27","author":"Giaccone","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cbi.2026.111951_bib97","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s10637-009-9333-6","article-title":"A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma","volume":"29","author":"Lewis","year":"2011","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.cbi.2026.111951_bib100","first-page":"968","article-title":"A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated","volume":"23","author":"Tolcher","year":"2012","journal-title":"prostate cancer. Ann Oncol"},{"key":"10.1016\/j.cbi.2026.111951_bib98","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1002\/cncr.26510","article-title":"A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell lymphoma","volume":"118","author":"Cheson","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.cbi.2026.111951_bib103","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s00280-012-1913-z","article-title":"Pharmacokinetics of sepantronium bromide (YM155), a small-molecule suppressor of survivin, in Japanese patients with advanced solid tumors: dose proportionality and influence of renal impairment","volume":"70","author":"Aoyama","year":"2012","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.cbi.2026.111951_bib101","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s10637-012-9867-x","article-title":"Population pharmacokinetic modeling of sepantronium bromide (YM155), a small molecule survivin suppressant, in patients with non-small cell lung cancer, hormone refractory prostate cancer, or unresectable stage III or IV melanoma","volume":"31","author":"Aoyama","year":"2013","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.cbi.2026.111951_bib102","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/bdd.1827","article-title":"Lack of differences in the pharmacokinetics of sepantronium bromide (YM155) between US and Japanese patients with advanced solid tumors or Non-Hodgkin lymphoma","volume":"34","author":"Aoyama","year":"2013","journal-title":"Biopharm Drug Dispos."},{"key":"10.1016\/j.cbi.2026.111951_bib104","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1093\/annonc\/mdt249","article-title":"A phase I\/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer","volume":"24","author":"Kelly","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.cbi.2026.111951_bib106","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s10549-014-3238-6","article-title":"Phase II, multicenter, open-label, randomized study of YM155 plus docetaxel as first-line treatment in patients with HER2-negative metastatic breast cancer","volume":"149","author":"Clemens","year":"2015","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.cbi.2026.111951_bib105","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/cam4.363","article-title":"A phase 2, multicenter, open-label study of sepantronium bromide (YM155) plus docetaxel in patients with stage III (unresectable) or stage IV melanoma","volume":"4","author":"Kudchadkar","year":"2015","journal-title":"Cancer Med."},{"key":"10.1016\/j.cbi.2026.111951_bib107","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.3109\/10428194.2015.1113275","article-title":"A multicenter phase II study of sepantronium bromide (YM155) plus rituximab in patients with relapsed aggressive B-cell Non-Hodgkin lymphoma","volume":"57","author":"Papadopoulos","year":"2016","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.cbi.2026.111951_bib108","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s00280-020-04112-1","article-title":"Phase I safety and pharmacokinetic study of YM155, a potent selective survivin inhibitor, in combination with erlotinib in patients with EGFR TKI refractory advanced non-small cell lung cancer","volume":"86","author":"Shimizu","year":"2020","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.cbi.2026.111951_bib109","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.nucmedbio.2018.06.005","article-title":"Predicting response to sepantronium bromide (YM155), a survivin suppressant, by PET imaging with [11C]YM155","volume":"64\u201365","author":"Mitsuoka","year":"2018","journal-title":"Nucl. Med. Biol."}],"container-title":["Chemico-Biological Interactions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009279726000591?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009279726000591?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T17:18:58Z","timestamp":1770830338000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009279726000591"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":109,"alternative-id":["S0009279726000591"],"URL":"https:\/\/doi.org\/10.1016\/j.cbi.2026.111951","relation":{},"ISSN":["0009-2797"],"issn-type":[{"value":"0009-2797","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular actions of sepantronium bromide (YM155) on survivin-dependent cell death in cancer and beyond","name":"articletitle","label":"Article Title"},{"value":"Chemico-Biological Interactions","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cbi.2026.111951","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"111951"}}